B-Cell Navigator is a dual-engine platform for rapid, scalable discovery of target-specific antibodies at single-B-cell resolution, from the full immune repertoire

MR. Guimarães [1], M. Lisetto [1], A. C. Trigo [1], A. I. Soares [1], O. Fomochova [1], I. Silva [1], J. Canossa [1], S. Lemos [1] I. Toth [1], J. Queiroz [1] and T. P. Resende [1]

>1,000-fold multiparameter optimisation of an enzyme inhibitor to generate a best-in-class antibody. First human dosed within 18 months of programme initiation. Now in Phase 3.

Biologics for companion animals are advancing, but the reporter cell lines needed to characterise them are often not commercially available, with little supporting literature. FairJourney Bio engineered two custom reporter cell lines, for a dual-chain receptor and a GPCR, to evaluate blocking antibodies in animal health. Both reached IND-ready status with validated IC50 readouts, in under 3.5 months from vector design to clone delivery.

FairJourney Bio state-of-the-art cryo-EM facility in San Diego delivers high-quality structural data within accelerated timelines.

It combines naive, semi-synthetic, immune, and named libraries with phage, mammalian, yeast, and single B-cell platforms in one customisable workflow, so the route to a candidate follows your biology rather than a single platform. Developability is built in from the start through patent-protected mammalian display, not patched after a failed lead. The fact sheet sets out the libraries, platforms, formats, and tough-target applications behind any target, any format.